Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics

Buszewski, Bogusław; Ulanowska, Agnieszka; Kowalkowski, Tomasz; Cieśliński, Krzysztof

doi:10.1515/cclm.2011.769

Cited by 52 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, aside from D-mannose , we could find clear association of these metabolites with cancer. For example, in [23], a higher release of acetone was found in breath of lung cancer patients than in healthy volunteers. In addition, a lower level of acetoacetate was found in malignant pleural effusions [24].…”

Section: Resultsmentioning

confidence: 98%

In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes

et al. 2014

View full text Add to dashboard Cite

Metabolism expresses the phenotype of living cells and understanding it is crucial for different applications in biotechnology and health. With the increasing availability of metabolomic, proteomic and, to a larger extent, transcriptomic data, the elucidation of specific metabolic properties in different scenarios and cell types is a key topic in systems biology. Despite the potential of the elementary flux mode (EFM) concept for this purpose, its use has been limited so far, mainly because their computation has been infeasible for genome-scale metabolic networks. In a recent work, we determined a subset of EFMs in human metabolism and proposed a new protocol to integrate gene expression data, spotting key 'characteristic EFMs' in different scenarios. Our approach was successfully applied to identify metabolic differences among several human healthy tissues. In this article, we evaluated the performance of our approach in clinically interesting situation. In particular, we identified key EFMs and metabolites in adenocarcinoma and squamous-cell carcinoma subtypes of non-small cell lung cancers. Results are consistent with previous knowledge of these major subtypes of lung cancer in the medical literature. Therefore, this work constitutes the starting point to establish a new methodology that could lead to distinguish key metabolic processes among different clinical outcomes.

show abstract

Section: Resultsmentioning

confidence: 98%

In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Using these technologies, several promising biomarkers have been identifi ed in the breath of cancer patients. For example, Buszewski et al (31) analyzed volatile organic compounds released by non-small cell lung cancer (NSCLC) explants cultured in vitro and in the breath of NSCLC patients using solid phase micro-extraction and gas chromatography/ mass spectrometry, and noted marked differences of volatile organic compound concentrations in the breath of patients and controls. The presence of tumor-specifi c biomarkers in the breath that may be detected by a very sensitive olfactory system of some animal species, e.g., dogs, also represents an explanation for the phenomenon of canine olfactory detection of cancer (39,40) .…”

Section: Bohuslav Melicharmentioning

confidence: 99%

Tumor biomarkers: PSA and beyond

Melichar

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

“…The authors analyzed volatile organic compounds released by non-small-cell lung cancer (NSCLC) explants cultured in vitro and in the breath of NSCLC patients. Marked differences in volatile organic compound concentrations were noted in the breath of patients and controls (14) . It is possible that these differences are detected by animals with a very sensitive olfactory system, for example, dogs.…”

mentioning

confidence: 96%

“…This more conventional approach of utilization of laboratory medicine in the management of cancer patients is highlighted in the current issue of Clinical Chemistry and Laboratory Medicine by several papers (2,13,14) and in an article by Soh et al recently published in this Journal (15).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cancer diagnosis: from dogs to DNA or from DNA to dogs?

Melichar

Plebani

2012

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Laboratory medicine plays an increasingly important role in the management of cancer patients (1) . The involvement of laboratory medicine in clinical oncology is based on the concept of biomarkers. A biomarker may be defi ned as a parameter that can be detected in the laboratory and is associated with malignant transformation or tumor progression. The utilization of biomarkers encompasses predicting the subject ' s risk of cancer [e.g., determining BRCA1 mutation to identify individuals with high risk of breast and ovarian cancer (2) ], contributing to the diagnosis [e.g., utilization of tumor markers for pre-operative diagnosis of ovarian cancer (3, 4) ], predicting the prognosis and response to therapy, or monitoring the therapeutic response or detecting the recurrence. Biomarkers are also used to assess the toxicity of anti-cancer therapy (5) .In the current issue of Clinical Chemistry and Laboratory Medicine Lippi and Cervellin (6) present a rather provocative topic that may seem in stark contrast with the prevalent " conventional " use of laboratory diagnostics in cancer medicine. The authors summarize the experience with canine olfactory detection of cancer from early anecdotal reports to subsequent prospective studies. The scientifi c foundations of canine olfactory detection are also thoroughly reviewed and the pitfalls of this approach in cancer screening, including the problems already identifi ed, or potential confounding issues yet to be investigated are also addressed.The interest in cancer screening was prompted mainly by dramatic differences in survival rates of patients with malignant tumors according to the stage at diagnosis. Early detection through screening programs has resulted in increased survival of patients with breast cancer, cervical cancer or prostate cancer (7,8) . In addition, the therapy of advanced tumors is much more expensive compared to tumors detected at an early stage. Thus, early detection markedly increases cost-effectiveness of therapy. Unfortunately, for the malignant tumors of most primary locations an effective screening still remains an unfulfi lled dream.The idea of using dogs for cancer screening may seem odd at fi rst glance and evokes to some readers the specter of alternative medicine. Physicians who have some experience with uses (or rather abuses) of so-called alternative medicine may be alarmed by the perspective of barking of a dog in a doctor ' s offi ce or clinical laboratory forming the basis of important medical decisions. However, everyone is familiar from daily life with the use of canine olfactory detection to detect explosives or illicit drugs, and the use of canine olfactory detection for security or forensic purposes is a generally accepted practice. The use of dogs is well established in forensic medicine, for example, for searching for human remains (cadaver dogs) (9) or in fi re investigations (10) . Why then should this " technology " not be acceptable for diagnosis of today ' s most dreaded disease ? Frankly speaking, for most tumors we do not ...

show abstract

Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics

Abstract: Detection of lung cancer is possible by volatile biomarkers analysis in breath.

Cited by 52 publications

References 26 publications

In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes

In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes

Tumor biomarkers: PSA and beyond

Cancer diagnosis: from dogs to DNA or from DNA to dogs?

Contact Info

Product

Resources

About